Navigation Links
CMC Biologics Licenses Its CHEF1® Expression System to Oxford BioTherapeutics
Date:9/7/2011

Terrett, OBT's Chief Scientific Officer.

"CMC Biologics is delighted to provide its CHEF1 expression system to OBT," said Mads Laustsen, Chief Scientific Officer of CMC Biologics. "We believe the advantages of the CHEF1 system will help OBT generate cell lines in a highly efficient and effective way."

About Oxford BioTherapeutics

Oxford BioTherapeutics (OBT) is a leading international biotechnology company focused on the development and commercialization of innovative antibody-based cancer medicines, with integrated diagnostics, against novel targets that it has discovered in its unique OGAP® proteomic database. OBT accesses leading antibody technologies and expertise through its partnerships with many of the world leaders in antibody development, including the BMS (Medarex) HuMAb platform, the Amgen (Abgenix) Xenomouse™ platform, the transgenic phage technology of Alere (formerly Biosite) and the POTELLIGENT® Technology of BioWa, and through its development alliances with GSK and Sanofi-Aventis. OBT's diagnostic collaboration with Alere also provides the opportunity to develop tailored diagnostics for OBT's therapeutic products. These partnerships have enabled OBT to use its unique position to convert its novel oncology targets into a highly attractive pipeline of therapeutic antibodies. OBT's pipeline will deliver innovative and cost-effective first-in-class medicines to fulfil major unmet patient needs in the field of cancer.

For further information, please see www.OxfordBioTherapeutics.com

About CMC Biologics

CMC Biologics (www.cmcbio.com) is a dedicated contract biopharmaceutical manufacturing and development organization with facilities in Copenhagen, Denmark and Seattle, Washington, USA. CMC Biologics specializes in custom services for scale up and cGMP manufacture of protein-based therapeutics for pr
'/>"/>

SOURCE CMC Biologics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Dr. Lester Mandelker to Collaborate with Nuovo Biologics, LLC
2. Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA
3. New Conference Offers Solutions for Success in the Growing Biologics Market
4. CMC Biologics Expands Its Production Facility and Rebrands Its Corporate Identity
5. Oncobiologics, Inc. to Unveil New Biologics Proof-of-Concept Engine at BIO International Convention
6. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
7. Bacterin International Signs Its Second National GPO Contract for Bacterin Biologics and Its First For Wound Drains with ROi
8. Reportlinker Adds Whats Next in Biologics? (mAbs, rDNA, Interferons, and Other Biologics) 2011-2015
9. Pfenex Inc., Through Its Reagent Proteins Business Division, Announces Submission of Biologics Master File for Recombinant CRM197 to US FDA
10. Pioneer® Surgical Technology, Inc. Enters the Biologics Extremities and Pelvis Market
11. Aperion Biologics Initiates Clinical Trial of Z-Lig™ Device for Anterior Cruciate Ligament Reconstruction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... -- Smith & Nephew (LSE:SN, NYSE: SNN ... its entry into the forefoot market with the ... Comprised of three separate repair options, the HAT-TRICK ... and reconstruction, a metatarsal osteotomy guide, and a ... also known as hammer toe correction. ...
(Date:7/31/2014)... July 31, 2014 The global market ... million by 2020, according to a new study by ... and theranostics, and the subsequent introduction of advanced cancer ... market growth over the next six years. Moreover, the ... such as cancer, coupled with disease triggering lifestyle habits ...
(Date:7/31/2014)... 31, 2014 SoundConnect , ... company, is proud to announce the addition of ... Adobe Connect’s elearning tools to quickly deploy and ... with training tools for desktop and mobile learning ... is the perfect online training solution, enabling organizations ...
(Date:7/30/2014)... JOLLA, Calif. , July 30, 2014 ... ), a biopharmaceutical company leading the discovery and development ... will report financial results and highlights for the quarter ... after the U.S. financial markets close. ... Wednesday, August 6, 2014, at 5:00 pm Eastern Daylight ...
Breaking Biology Technology:Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 2Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 3Smith & Nephew scores a HAT-TRICK with its entry into the high-growth hammer toe repair market 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 2Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 3Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 4Molecular Diagnostics Market - Global Industry Size, Share, Trends, Analysis, Players, Opportunity, Outlook and Forecast From 2014 to 2020 5SoundConnect Enhances Portfolio with Adobe Connect Learning Management System (LMS) 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 2Regulus Announces Timing for Second Quarter 2014 Financial Results Webcast and Conference Call 3
... N.Y., June 25 Lixte,Biotechnology Holdings (OTC Bulletin ... Neurological Disorders and Stroke (NINDS), National,Institutes of Health ... Research and Development Agreement (CRADA) to develop,drugs for ... in March,2006 was extended through September 2009., ...
... MichBio announced that,Johnson & Johnson Vice Chairman, Christine A. ... and Conference November 18-19 in Novi,Michigan. MichBio is the ... is the state,s premier life science event attracting,more than ... is one of the most respected professionals in the ...
... titled “Avanta AC™ Advanced Ceramics Solutions as ... white paper outlines the challenges in manufacturing ... as well as the advantages of SACHEM’s ... are critical to a variety of leading ...
Cached Biology Technology:Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 2Lixte Biotechnology Holdings Announces Extension of Its Cooperative Research and Development Agreement With The National Institute of Neurological Disorders and Stroke, National Institutes of Health, for Development of Anti-Brain Cancer Drugs 3Christine Poon Will Keynote MichBio Expo 2Christine Poon Will Keynote MichBio Expo 3 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2
(Date:7/30/2014)... epigenetic processes to regulate its genes, and adapt to ... of the genome regulation taking place in the truffle, ... Biology and illustrates how the truffle deals with ... authors say this may shed light on how traits ... (Tuber melanosporum), also known as Prigord truffles, have a ...
(Date:7/30/2014)... effects of climate change on the world,s animal ... factors, according to a new paper by a ... of Queensland, and other organizations. The authors claim ... the point when it comes to climate change. ... scientists focus on the "direct" threats of changing ...
(Date:7/30/2014)... The San Antonio Life Sciences Institute (SALSI), a joint ... (UTSA) and The University of Texas Health Science Center ... Postdoc Initiative Pilot Program. The winners, Emily Boice from ... will receive $25,000 for their project titled, "Novel engineered ... post-ischemic environment." , Boice and Huang,s research is focused ...
Breaking Biology News(10 mins):How black truffles deal with the jumpers in their genome 2Conservation scientists asking wrong questions on climate change impacts on wildlife 2
... 2013 The Damon Runyon Cancer Research Foundation ... its spring 2013 Clinical Investigator Award Committee review. ... are outstanding early career physician-scientists conducting patient-oriented cancer ... of the nation,s leading scientists and clinicians. ...
... other conditions caused by malfunctions in the body,s nerve ... treat. The problem is that one medicine may help ... which drugs will work with individual patients may be ... seemingly identical neurons can behave the same even though ...
... discovered a mechanism that triggers chronic inflammation in ... today in Nature Immunology , suggest a ... the way to a new class of therapies ... diseases without crippling the immune system. Alzheimer,s, atherosclerosis ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 2Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 3Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 4Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 5Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 6Damon Runyon Cancer Research Foundation awards $3.6 M to 9 top young clinical investigators 7Nerve cells can work in different ways with same result 2Researchers discover new way to block inflammation 2
RNA polymerase sigma 70 Immunogen: Recombinant, full length protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Anti-Dardarin Immunogen: Synthetic peptide from rat LRRK2. Available Date: 38814...
Rat monoclonal to UGGT ( Abpromise for all tested applications)....
... Rabbit polyclonal to MSY2/YBOX2 ( Abpromise ... Antigen: Synthetic peptide ... the C-terminus of Human MSY2/YBOX2. ... proprietary) (Peptide available ...
Biology Products: